Title |
Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
|
---|---|
Published in |
PLOS ONE, February 2013
|
DOI | 10.1371/journal.pone.0057289 |
Pubmed ID | |
Authors |
Heloisa P. Soares, Yang Ni, Krisztina Kisfalvi, James Sinnett-Smith, Enrique Rozengurt |
Abstract |
The mTOR pathway is aberrantly stimulated in many cancer cells, including pancreatic ductal adenocarcinoma (PDAC), and thus it is a potential target for therapy. However, the mTORC1/S6K axis also mediates negative feedback loops that attenuate signaling via insulin/IGF receptor and other tyrosine kinase receptors. Suppression of these feed-back loops unleashes over-activation of upstream pathways that potentially counterbalance the antiproliferative effects of mTOR inhibitors. Here, we demonstrate that treatment of PANC-1 or MiaPaCa-2 pancreatic cancer cells with either rapamycin or active-site mTOR inhibitors suppressed S6K and S6 phosphorylation induced by insulin and the GPCR agonist neurotensin. Rapamycin caused a striking increase in Akt phosphorylation at Ser(473) while the active-site inhibitors of mTOR (KU63794 and PP242) completely abrogated Akt phosphorylation at this site. Conversely, active-site inhibitors of mTOR cause a marked increase in ERK activation whereas rapamycin did not have any stimulatory effect on ERK activation. The results imply that first and second generation of mTOR inhibitors promote over-activation of different pro-oncogenic pathways in PDAC cells, suggesting that suppression of feed-back loops should be a major consideration in the use of these inhibitors for PDAC therapy. In contrast, metformin abolished mTORC1 activation without over-stimulating Akt phosphorylation on Ser(473) and prevented mitogen-stimulated ERK activation in PDAC cells. Metformin induced a more pronounced inhibition of proliferation than either KU63794 or rapamycin while, the active-site mTOR inhibitor was more effective than rapamycin. Thus, the effects of metformin on Akt and ERK activation are strikingly different from allosteric or active-site mTOR inhibitors in PDAC cells, though all these agents potently inhibited the mTORC1/S6K axis. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 1% |
Brazil | 1 | 1% |
Belgium | 1 | 1% |
Korea, Republic of | 1 | 1% |
United States | 1 | 1% |
Unknown | 84 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 30 | 34% |
Researcher | 13 | 15% |
Student > Bachelor | 10 | 11% |
Student > Doctoral Student | 7 | 8% |
Student > Master | 7 | 8% |
Other | 13 | 15% |
Unknown | 9 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 22 | 25% |
Medicine and Dentistry | 20 | 22% |
Biochemistry, Genetics and Molecular Biology | 19 | 21% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
Immunology and Microbiology | 3 | 3% |
Other | 6 | 7% |
Unknown | 13 | 15% |